



Current Topics in Genome Analysis 2014

Laura Elnitski, Ph.D.

No Relevant Financial Relationships with Commercial Interests

From blueprint to implementation

I. Genome composition

II. Enhancer studies


III. Epigenetics




"What ever will we think about now that the genome project is almost complete?"

Genomics spurs rapid advancement






An image of tau tangles in the brain, often a hallmark of Alzheimer's disease. A group of researchers has found that a protein, normally active in fetuses, may also protect the neurons in older people. Yankner laboratory







June 26, 2000



Brain Mapping Project



Baby Genome





TCGA

Disease risk associations

Personalized medicine

\$1000 genome







DEBATES

HOW MUCH OF THE GENOME IS FUNCTIONAL?

HOW MUCH OF THE GENOME IS SUPERFLUOUS? how to be sure?

HOW WELL CAN WE DISTINGUISH THE TWO? biochemical signals, conservation, genetic evidence







Complexity

- Cell-type diversity
- Coding genome
 - Alleles
 - Splicing isoforms
 - Regulated translation
 - Posttranslational modifications
- Noncoding RNA
- Noncoding genome
 - Alternative promoters
 - Alternative 3' UTRs
 - Myriad enhancers
 - Intronic regulatory elements
 - Replication origins
- Epigenetic modifications





www.dkfz.de







Genome challenges



Thea Norman (Official Rep) 4 months ago


Welcome to the ICGC-TCGA-DREAM Somatic Mutation Calling Challenge


The Undiagnosed Diseases Program





- Overview
- O Program Background
- Program News
 Program Contact
- 0 _____

























































Determining biochemically active regions


- Transcription factor occupancy
- DNase Hypersensitivity
- FAIRE data
- Chromatin modifications











Deletion of candidate elements

Deletion of Ultraconserved Elements Yields Viable Mice

Nadav Ahituv^{1,2}^u, Yiwen Zhu¹, Axel Visel¹, Amy Holt¹, Veena Afzal¹, Len A. Pennacchio^{1,2}, Edward M. Rubin^{1,2*}

1 Genomics Division, Lawrence Berkeley National Laboratory, Berkeley, California, United States of America, 2 United States Department of Energy Joint Genome Institute, Walnut Creek, California, United States of America

Ultraconserved elements have been suggested to retain extended perfect sequence identity between the human, mouse, and rat genomes due to essential functional properties. To investigate vivo, we removed four noncoding ultraconserved elements (ranging in length from the mouse genome. To maximize the likelihood of observing a phenotype, we chose enhancers in a mouse transgenic assay and that are near genes that exhibit marke inactivated in the mouse and when their expression is altered due to other genomi resulting lines of mice lacking these ultraconserved elements were viable and feabnormalities when assayed for a variety of phenotypes including growth, longs addition, more targeted screens, informed by the abnormalities observed in mice investigated elements had been altered, also failed to reveal notable abnormalitie verification of all the possible phenotypic impact of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable also failed to reveal notable abnormalities of the deleted sequences, indicate that expression is altered also failed to reveal notable and feabnormalities of the deleted sequences, indicate that expression is altered also failed to reveal the deleted sequences are also failed to reveal the deleted sequences are also failed to r


GWAS summary


- Resounding success
- Modest effects (OR < 2)
- Substantial heritability remains to be explained


Deep resequencing of GWAS loci identifies independent rare variants associated with inflammatory bowel disease


Manuel A Rivas¹⁻³, Mélissa Beaudoin^{4,23}, Agnes Gardet^{5,23}, Christine Stevens^{2,23}, Yashoda Sharma⁶, Clarence K Zhang⁶, Gabrielle Boucher⁴, Stephan Ripke^{1,2}, David Ellinghaus⁷, Noel Burtt², Tim Fennell², Andrew Kirbyl^{1,2}, Anna Latiano⁸, Philippe Goyette⁴, Todd Green², Jonas Halfvarson⁹, Talin Haritunians¹⁰, Joshua M Korn², Finny Kuruvilla^{2,11}, Caroline Lagacé⁴, Benjamin Neale^{1,2}, Ken Sin Lo⁴, Phil Schumm¹², Leif Törkvist¹³, National Institute of Diabetes and Digestive Kidney Disease Inflammatory Bowel Disease Genetics Consortium (NIDDK IBDGC)¹⁴, United Kingdom Inflammatory Bowel Disease Genetics Consortium¹⁴, International Inflammatory Bowel Disease Genetics Consortium¹⁴, Marla C Dubinsky¹⁵, Steven R Brant^{16,17}, Mark S Silverberg¹⁸, Richard H Duerr^{19,20}, David Altshuler^{1,2}, Stacey Gabriel², Guillaume Lettre⁴, Andre Franke⁷, Mauro D'Amato²¹, Dermot P B McGovern^{10,22}, Judy H Cho⁶, John D Rioux⁴, Ramnik J Xavier^{1,2,5} & Mark J Daly^{1,2}


genetics
















Regulatory modifications



Active enhancer




Repressed promoter


Writing

Erasing

Chromatin code




Reading



Acetylases, methylases, phosphorylases Deacetylases, demethylases, phosphatases

Bromodomain, chromodomain, PHD finger, WD40 repeat

Nature Immunology 11, 565–568 (2010)



Mutations of epigenome modifiers

Histone variants HIST1H1B

DNA methyltransferases DNMT1

DNA demethylases TET2

Histone acetyltransferases EP300


Histone deacetylases HDAC4


Histone methyltransferases MLL


Histone demethylases JARID1C

Chromatin remodelling factors ARID1A


Nature Reviews Cancer 13, 497–510 (2013)











Silencing Down syndrome






























MeCP2 and Rett Syndrome









NATURE GENETICS VOLUME 37 JANUARY 2005


Nutrition







Plausible health interventions









Conclusion



The central dogma has guided decades of research in molecular biology.

Sequencing of the human genome:

- · evolutionary diversity among species
- importance of noncoding sequences
- · detection of disease processes

Platform for understanding

Knowledge shapes the future







The appropriate Treatment At the appropriate Dose For the appropriate Patient At the appropriate Time For the appropriate Outcome